Introduction {#S1}
============

*Clostridioides* (*Clostridium*) *difficile*, a Gram-positive, spore-forming, obligate anaerobe, is the main cause of nosocomial infectious diarrhea in industrialized countries ([@B23]). The bacterium accounts for 20--30% of cases of antibiotic-associated diarrhea and is the most commonly recognized cause of infectious diarrhea in healthcare settings ([@B8]). The main risk factors for an initial episode of *C. difficile* infection (CDI) are antibiotic therapy, hospitalization, and underlying comorbidities. Older adults (≥65 years of age) are at increased risk for CDI, particularly when exposed to health care settings ([@B2]).

*C. difficile* can produce 3 toxins, toxin A (TcdA), toxin B (TcdB), and binary toxin (CDT) ([@B25]). TcdA and TcdB are large single subunit proteins (approximately 308 and 270 kDa, respectively), and are considered the principal virulence factors contributing to CDI ([@B48]). These two toxins have similar structural features delineated by four functional domains but share just 50% overall amino acid sequence identity. The C-terminal domain of the toxin proteins, known as the combined repetitive oligopeptide (CROP) domain, facilitates toxin binding to the surface of intestinal epithelial cells. The toxins enter the cell by endocytosis where the reduced pH of endocytic vesicles triggers a conformational change in the cell entry domain of the toxin, resulting in pore formation and translocation of the glucosyltransferase domain (GTD) and autoprocessing domain (APD) to the cytosolic face of the membrane. Binding of the cytosolic cofactor InsP6 activates the APD, resulting in cleavage and release of the GTD. GTD-catalyzed transfer of glucose inactivates small cytoplasmic GTPases of the Rho family of proteins, leading to the disruption of the cytoskeleton. This manifests as a cytopathic rounding effect and cell death in the epithelium which results in diarrhea. CDT belongs to the family of binary ADP-ribosylating toxins consisting of two components: CDTa (ADP-ribosyltransferase) and CDTb (responsible for host cell binding and translocation of CDTa to the cytosol). As *cdtA* and *cdtB* are not detected in all toxigenic isolates, the significance of CDT as a virulence factor contributing to CDI remains in question ([@B13]).

*C. difficile* infection often occurs when the integrity of the normal intestinal microbiota is disturbed. The spectrum of CDI presentation includes mild self-limiting to severe diarrhea which may progress to pseudomembranous colitis, toxic megacolon, intestinal perforation, and death ([@B3]). Although most patients experiencing a first episode of CDI respond well to standard antibiotic treatment (which can include metronidazole, vancomycin or fidaxomicin), approximately 15--35% of patients suffer from at least one recurrence ([@B32]). Immunoprophylactic approaches that target *C. difficile* toxins have been developed for the prevention of recurrent CDI ([@B43]). Vaccines have been successfully developed to prevent other toxin mediated diseases, such as tetanus and diphtheria, by inducing antibodies that neutralize the cytopathic effect of the toxin ([@B31]). The proposed mechanism of action of these approaches is through antibody mediated (both monoclonal antibody as well as vaccine-elicited polyclonal responses) neutralization of the cytotoxic activity of toxins produced by disease-causing *C. difficile* isolates.

Several molecular methods have been used to type *C. difficile* isolates for epidemiological studies. These include restriction endonuclease analysis (REA), pulse field gel electrophoresis (PFGE), and ribotyping, a PCR-based method that takes advantage of the size heterogeneity of the intergenic spacer region (ISR) between 16S and 23S rRNA genes ([@B30]; [@B33]; [@B17]). Isolates can also be classified by toxinotype, a restriction fragment length polymorphism (RFLP) method that is based on changes in the *C. difficile* pathogenicity locus (PaLoc) ([@B39]). *C. difficile* may also be grouped into five main clades and at least three additional cryptic clades based on the clustering of the concatenate multiple locus sequence typing (MLST) alleles ([@B21]). While each of these methods provides value for isolate characterization in epidemiological studies, none provides detailed insight to the diversity of full length TcdA and TcdB proteins. Reports on sequence-based variability within TcdA and TcdB toxins in large strain collections are uncommon. Sequence diversity within a 199 amino acid fragment of the CROP domain of TcdB (corresponding to the receptor binding domain of the toxin), has been used to differentiate toxin variant types ([@B10]). An understanding of toxin diversity among contemporary disease-causing isolates is essential for assessment of the immune response to the toxins. In this manuscript we report on the deduced amino acid sequence of TcdA and TcdB toxin proteins determined from whole genome nucleotide sequence data of 478 *C. difficile* isolates. A total of 44 TcdA and 37 TcdB protein variants have been identified among these isolates and are presented together with detailed molecular analyses.

Materials and Methods {#S2}
=====================

Strain Collection, Isolate Selection, Microbiology and DNA Isolation {#S2.SS1}
--------------------------------------------------------------------

Initially, a total of 504 *C. difficile* isolates, collected from multiple sources across several geographic regions between the years 2004--2018 were included in this study ([Table 1](#T1){ref-type="table"}). The isolates do not represent a prevalence-based collection. Whole genome sequence (WGS) data was collected for all isolates and the PCR ribotype was determined for each of the isolates. Toxinotype assignments were available for a subset of the isolates.

###### 

*Clostridioides difficile* isolates included in this study.

  Collection name                                             Collection year   Geographic origin                                                  Molecular typing            Number of isolates
  ----------------------------------------------------------- ----------------- ------------------------------------------------------------------ --------------------------- --------------------
  Legacy North America                                        2004--2009        United States, Canada                                              Ribotype, WGS               24
  Legacy United Kingdom                                       \<2011            United Kingdom                                                     Ribotype, WGS               26
  Antimicrobial Testing Leadership and Surveillance (ATLAS)   2009--2017        Belgium, Czech Republic, France, Germany, Hungary, Spain, Sweden   Ribotype, WGS               303
  Toxinotype diversity subset                                 2009--2016        Australia, Belgium, Germany, Slovenia, Spain, United Kingdom       Ribotype, Toxinotype, WGS   64
  United States contemporary                                  2015--2018        United States                                                      Ribotype, WGS               87

*C. difficile* isolates were either provided as glycerol stocks or were purified from stool specimens. All microbiology was conducted under anaerobic conditions. Glycerol stocks were plated onto Tryptone Soya Agar (TSA) + 5% sheep blood and incubated overnight at 37°C. On day 2, a single colony was selected and re-streaked onto a new TSA +5% sheep blood agar plate and again incubated overnight at 37°C. On day 3, colonies were transferred to a 96-well plate for lysis and genomic DNA was extracted using Beckman Coulter GenFind V2 kit (Indianapolis, IN, United States). For stool specimens, a 10 μl loop was used to transfer stool to 700 μL 95% ethanol; 20 μL of this suspension was then used to inoculate a cycloserine cefoxitin fructose agar plate, supplemented with horse blood and taurocholate (CCFA-HT) and incubated for 2 days at 37°C. On day 3, a single colony was picked from CCFA-HT plate and streaked onto a TSA blood agar plate followed by overnight incubation at 37°C. On day 4, the colonies were transferred to a 96-well plate for lysis and genomic DNA was extracted using the Beckman Coulter GenFind V2 kit.

Molecular Characterization of the Study Isolates {#S2.SS2}
------------------------------------------------

For the majority of strains, PCR-ribotyping was performed using the protocol described in [@B44]. For added discrimination, PCR products are analyzed using an Agilent 2100 Bioanalyzer. Ribotype and toxinotype assignments for the toxiontype diversity subset of strains were determined as described in [@B5] and [@B38], respectively. The nucleotide sequence of *adk, atpA, dxr, glyA, recA, sodA*, *and tpi* genes was extracted from the whole genome sequence of each strain and used to assign a sequence type (ST) and clade at PubMLST^[1](#footnote1){ref-type="fn"}^.

Preparation of the Illumina Sequencing Library {#S2.SS3}
----------------------------------------------

*C. difficile* sequencing libraries were prepared by using either the TruSeq DNA Sample Prep Kits ("TruSeq") or the Nextera DNA Flex Library Prep Kit ("Flex"), both from Illumina (San Diego, CA, United States). When using the TruSeq kit, genomic DNAs are first mechanically sheared by a Covaris ME220 (Woburn, MA, United States) sonication instrument using the settings recommended by the manufacturer. After sonication, the TruSeq universal adapters are added to the ends of the genomic DNA fragments by ligation, followed by bead cleanup, size selection and quantification according to the manufacturer's protocol. When using the Flex kit, genomic DNAs are first tagmented (transposon-mediated fragmentation) and universal adapters are added to the ends of the DNA fragments by PCR, according to the manufacturer's protocol. DNA libraries (paired end, 2 × 300) were loaded on the Illumina Miseq for whole genome sequencing of the respective *C. difficile* genomes.

Analysis of the WGS Data {#S2.SS4}
------------------------

Primary nucleotide sequence data for the 478 *C. difficile* isolates from this study has been deposited to NCBI SRA (BioProject [PRJNA600974](PRJNA600974)). Primary *C. difficile* DNA sequence reads were run through the "Merge Overlapping Pairs" program followed by assembly into contigs using the "De Novo Assembly" program in the Qiagen CLC Genomics Workbench (Redwood City, CA, United States) using default parameters. The *tcdA* and *tcdB* allele sequences were inferred by aligning the assembled contigs to the *tcdA* and *tcdB* sequences of the CD630 isolate (GenBank accession [AM180355](AM180355)) ([@B41]). The deduced amino acid sequences of the genes coding for TcdA and TcdB in CD630 are labeled as TcdA001 and TcdB001, respectively.

A unique toxin variant is defined as a TcdA or TcdB open reading frame (ORF) that includes all four of the functional domains and whose amino acid sequence differs by at least one amino acid from any other entry. The most challenging region for collection of high-quality DNA sequence was in the C-terminal CROP domain, particularly in the TcdA ORF. In some instances, these challenges were addressed by repeat sequencing with fewer input strains to achieve greater depth and/or by performing the *de novo* assembly program a second time without merging overlapping pairs. If the toxin variant could not be determined by the *de novo* assembly program, primary sequence data was aligned to the CD630 reference genome to confirm the presence of the gene.

The nomenclature developed by [@B9] has been used to describe a series of truncations and in-frame deletions predicted from the *tcdA* nucleotide sequence of some isolates. In these instances, the TcdA001 sequence is used as the reference when describing position in the ORF. A unique TcdA variant number has been assigned if sequence corresponding to the CROP domain is included in the truncated ORF. However, if the deduced amino acid sequence is truncated prior to the CROP domain, a TcdA variant was not assigned and the isolate has been labeled as "truncated at TcdA." In those isolates where the entire *tcdA* sequence is missing, the strain has been classified as "TcdA deletion." Acceptance criteria for each novel TcdA or TcdB variant identified required a minimum 35X nucleotide sequence coverage across the respective ORFs with less than 10% sequence heterogeneity. If these acceptance criteria were not met, the isolate was not included in the phylogenomic analysis. The WGS from 26 of the 504 isolates in the collection did not meet these acceptance criteria and were not included in these analyses. TcdA and TcdB amino acid sequences were aligned using CLC Genomics Workbench and aligned sequences were used to construct the phylogenetic tree using the unweighted pair group method with arithmetic mean (UPGMA) with bootstrapping. The phylogenomic figure was created by aligning assembled *C. difficile* genomes using Parsnp ([@B46]) with recombination filtration option enabled. The metadata (clade, ST, ribotype, TcdA variant type, and TcdB variant type) was plotted as concentric rings using a custom-built R program.

Measurement of Toxin Variant Diversity and Distribution Within Phylogenetic Clades {#S2.SS5}
----------------------------------------------------------------------------------

The Simpson's Diversity Index (SDI) was used to quantitatively measure the diversity and distribution of toxin variants within phylogenetic clades of *C. difficile*. The higher the index obtained, the greater the number and distribution of the toxin variants observed within a clade. Likewise, the lower the index, the fewer number of variants and/or a more restricted distribution of the toxin variants within a clade.

Results {#S3}
=======

Phylogenetic Analysis of TcdA and TcdB Variants {#S3.SS1}
-----------------------------------------------

Nucleotide sequence corresponding to *tcdA* and *tcdB* was extracted from the WGS data and used to generate the deduced amino acid sequence of TcdA and TcdB protein variants, respectively. To serve as a point of reference, the TcdA and TcdB proteins coded for by strain CD630 are variants TcdA001 and TcdB001. A total of 43 unique TcdA variants that differ from variant TcdA001 were identified. All TcdA variants were closely related, with pairwise amino acid sequence identity to TcdA001 that ranged from 98.0 to \>99.9%. From the deduced amino acid sequence of TcdA variants, an unrooted phylogenetic tree was constructed using the UPGMA ([Figure 1A](#F1){ref-type="fig"}). The toxin variant used as template to make the TxdA vaccine antigen (TcdA001) is grouped together with 21 other TcdA variants, with each variant sharing \>99.7% amino acid sequence identity with TcdA001. Of the TcdA variants whose ORF is at least 2,710 amino acids in length, TcdA013 was the most diverse (98.0% sequence identity with TcdA001) and is grouped with three others. Variant TcdA007 and TcdA016 (98.2 and 98.4% sequence identity with TcdA001, respectively), are phylogenetically related to several other full-length variants. Finally, TcdA019 which shares 98.5% identity with TcdA001, is representative of a fourth group of variants on the TcdA phylogenetic tree. Most of the sequence variation among the 44 TcdA variants is due to single amino acid substitutions. The greatest amino acid sequence diversity among the TcdA variants is found within the CROP domain of the proteins ([Table 2](#T2){ref-type="table"}). The *tcdA* nucleotide sequence of 25 isolates predict ORFs that are shorter than TcdA001 (summarized in [Supplementary Table 1](#TS1){ref-type="supplementary-material"}). A termination codon in the TcdA sequence from 14 isolates occurs following amino acid residue 46 (p.Q47^∗^) ([@B47]). While these isolates were collected in different geographic regions, including the United States and multiple European countries, each is genotyped as ST37/RT017. The *tcdA* sequence of three additional isolates also predicted termination codons within the GTD domain of the toxin (p.V57^∗^, p.D108^∗^, p.P196^∗^). A common termination codon (p.G699^∗^) in the APD domain is shared by three isolates. Since the predicted TcdA ORFs of these 20 isolates lack at least 3 of the functional toxin domains, TcdA variants were not assigned. Novel TcdA variants were assigned for 5 isolates whose *tcdA* sequence predict a deletion of a portion of the CROP domain of the toxin. In-frame deletions of 33 (TcdA050) and 175 amino acids (TcdA051) were detected in two isolates, while three isolates had termination codons in the TcdA CROP domain (TcdA052, TcdA053, TcdA054). Critical catalytic residues within the GTD (D285 and D287) and APD domains (C700) of the toxins are conserved among each of the 44 unique TcdA variants.

![Phylogenetic tree of TcdA **(A)** and TcdB **(B)** toxin variants. The amino acid sequences of the 44 TcdA variants and 37 TcdB variants were used to build the phylogenetic trees using CLC Genomics workbench with the UPGMA method. Each branch represents a unique toxin variant. The length of each branch corresponds to the amino acid sequence diversity from the TcdA001 **(A)** or TcdB001 **(B)** variants. The numbers in parentheses represent the pairwise amino acid sequence identity of representative variants to TcdA001 or TcdB001. The position of the TcdA001 and TcdB001 variant sequences from the CD630 isolate is highlighted with an arrow.](fmicb-11-01310-g001){#F1}

###### 

Pairwise amino acid sequence identity (%) of a subset of diverse TcdA and TcdB variants to TcdA001 and TcdB001, respectively.

                     Entire protein   Glucosyl transferase   Auto protease   Cell entry   Binding (CROP)
  ------------------ ---------------- ---------------------- --------------- ------------ ----------------
  **TcdA variant**                                                                        
  TcdA013            98.0             99.5                   99.2            98.6         96.1
  TcdA007            98.2             99.5                   99.6            98.6         96.5
  TcdA020            98.2             99.5                   99.6            98.8         96.3
  TcdA019            98.5             99.6                   99.2            99.0         96.8
  TcdA014            99.7             100                    100             99.6         99.7
  **TcdB variant**                                                                        
  TcdB032            86.1             79.2                   90.2            87.9         87.6
  TcdB011            87.0             79.4                   90.2            89.4         88.4
  TcdB019            88.4             79.2                   90.6            91.7         90.4
  TcdB002            92.2             96.5                   97.3            90.6         88.4
  TcdB003            93.7             79.0                   90.6            99.2         99.4
  TcdB015            99.8             100                    100             99.9         99.4

There were 31 non-toxigenic isolates, lacking any sequence corresponding to TcdA and TcdB (TcdA−/TcdB−). These were not restricted to a single ST or RT. A subset of 3 strains code for a full length TcdB variant, but without any *tcdA* sequence (TcdA−/TcdB+). These TcdA−/TcdB+ strains were also associated with multiple ribotypes. Precedent for both TcdA−/TcdB+ as well as non-toxigenic TcdA−/TcdB− *C. difficile* strains is well established in the literature ([@B37]).

The amino acid sequences of TcdB variants were more diverse than TcdA. Of the 36 variants that differed from TcdB001, pairwise amino acid sequence identity with TcdB001 ranged from 86.1 to \>99.9%. This is illustrated in the phylogenetic tree of TcdB variants ([Figure 1B](#F1){ref-type="fig"}). A total of 19 variants group together with TcdB001 (\>99.8% pairwise sequence identity). Variants TcdB032 and TcdB038 are the most diverse, sharing 86.1 and 86.2% sequence identity with TcdB001, respectively. TcdB032 is detected in one isolate in the collection (typed as ST62 and RT591) and two isolates code for TcdB038 (ST567 and RT095). While sequence diversity is detected in each of the functional domains of the TcdB toxin, the greatest diversity is found within the GTD domain ([Table 2](#T2){ref-type="table"}). Unlike TcdB001, eleven of the TcdB variants have a lysine inserted in the GTD domain (p.Val307_Thr308insLys). Based on the structure of the TcdB GTD domain (PDB ID 2BVM^[2](#footnote2){ref-type="fn"}^) ([@B36]), this additional amino acid residue is not predicted to impact the conformation of the GTD domain. The eleven sequence variants that contain the additional amino acid cluster to two groups on the TcdB phylogenetic tree ([Figure 1B](#F1){ref-type="fig"}). Critical catalytic residues of GTD (D286 and D288) and autoprotease (C698) domains are conserved among all TcdB variants. Although the TcdA and TcdB toxins share similar architectural homology with respect to the functional domains of the molecules, the pairwise amino acid sequence identity between TcdA001 and TcdB001 is only 42%.

More than half of the isolates (*n* = 292, 61%) in this study did not code for binary toxin ([Supplementary Table 2](#TS2){ref-type="supplementary-material"}). Each of the 31 non-toxigenic TcdA−/TcdB− isolates was binary toxin negative (genotyped as *cdtA*−*/cdtB*−). Considerable differences in TcdA and TcdB variant type and prevalence were also noted when comparing binary toxin positive and negative subsets of isolates. With very few exceptions, TcdA and TcdB variant types were selectively associated with either binary positive or binary negative isolates. Exceptions include variants TcdA007 and TcdB002. TcdA007 is coded for by just one of 292 binary negative isolates (0.3%) and 94/186 (50.5%) binary positive isolates. Similarly, the gene coding for TcdB002 is detected in just one binary negative strain but in 108/186 (58.1%) binary positive strains. This is particularly noteworthy as the *C. difficile* pathogenicity locus is not linked to the binary toxin alleles ([@B13]).

Phylogenomic Analysis and the Association of *C. difficile* Epidemiological Markers With Toxin Variant Type {#S3.SS2}
-----------------------------------------------------------------------------------------------------------

The 478 *C. difficile* genomes were assembled to construct a phylogenomic tree using Parsnp ([Figure 2](#F2){ref-type="fig"}). The nucleotide sequence of isolate CD630 was used as the reference genome. Each branch of the dendrogram is representative of a *C. difficile* isolate. Metadata descriptive of each isolate ([Supplementary Table 2](#TS2){ref-type="supplementary-material"}), including clade, ST, ribotype and toxin variant type, has been added as concentric rings to the circumference of the phylogenomic tree. Included among the 478 isolates are 61 ribotypes and 71 sequence types (STs). Comparative analysis afforded by the figure helps to illustrate that these epidemiological markers are not predictive of toxin variant type. Starting at 12 o'clock on the tree and traveling counterclockwise to 10 o'clock is a cluster of 107 isolates that are typed as ST1 and all code for TcdB variant TcdB002. Although most isolates in this cluster are ribotype 027, other ribotypes such as 081, 176, 027/198, and 198 are also identified. Continuing counter-clockwise on the tree is a cluster of 42 isolates that are typed as ST11 and code for TcdB variant TcdB004. Despite sharing considerable phylogenomic, ST and TcdB variant type similarities, the ribotype variability among these isolates is considerable, including ribotypes 045, 078, 126, 078/126, and 413.

![Phylogenomic tree of *C. difficile* isolates with accompanying meta data. The whole genome sequence of *C. difficile* isolates was used to construct a tree to illustrate the phylogenomic relationship among the isolates. *C. difficile* isolate CD630 (GenBank accession [AM180355](AM180355)) was used as the reference genome during the alignment. The position of the CD630 genome is highlighted by an arrow on the tree. Each branch of the dendrogram tree corresponds to a *C. difficile* isolate in the collection. From the innermost circle to the outermost circle, the five color-coded concentric circles identify clade, ST, ribotype, TcdA, and TcdB variant type assignments for each isolate. For clarity, ST and ribotype assignments identified in less than or equal to 6 isolates were colored as dark gray and light blue, respectively. Clade assignment could not be made in two instances (entered as not defined). TcdA and TcdB variants detected just once in the collection (singletons) are colored as black and blue, respectively.](fmicb-11-01310-g002){#F2}

Among the numerous methods that have been developed for molecular typing of *C. difficile* isolates, ribotype is most commonly cited. Analysis of WGS data in this study illustrates that isolates grouped by ribotype code for sequence-diverse toxin variants ([Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}). Among the 21 isolates that are grouped as ribotype 078/126, genes coding for three TcdA variant types (TcdA013, TcdA015, TcdA046) were identified. The ribotype 078/126 isolates also code for three TcdB variants (TcdB004, TcdB006, TcdB012) whose amino acid sequence identity to TcdB001 ranges from 96.1 to 99.9%. Ribotype 014/020 isolates in the collection code for four unique TcdA and six TcdB variants. The pairwise identity of the six TcdB variants to TcdB001 ranges from 92.2 to 99.9%.

###### 

*C. difficile* isolates grouped by ribotype can code for multiple and sequence diverse TcdA variants.

  TcdA variant^1^   Ribotype (number of isolates)                                                                    
  ----------------- ------------------------------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
  001               --                              --   --   --   --   --   --   1    --   --   --   --   --   --   --
  002               --                              --   --   --   --   7    3    --   --   --   --   --   16   --   --
  003               --                              --   --   --   3    --   --   --   4    --   --   --   --   --   --
  005               --                              --   --   --   2    --   --   --   --   --   --   --   --   --   --
  007               --                              --   --   --   --   --   81   --   --   --   --   --   --   --   --
  008               --                              --   --   --   --   --   --   --   2    --   --   --   --   --   --
  009               --                              --   --   1    --   --   --   --   --   --   --   --   --   --   --
  010               35                              21   --   1    40   2    --   --   2    --   --   --   1    --   1
  011               --                              --   --   --   --   --   --   --   11   --   --   --   --   --   1
  012               --                              --   --   --   --   --   --   5    --   --   --   --   --   --   --
  013               --                              --   --   --   --   --   --   --   --   --   11   18   --   10   --
  014               1                               --   --   3    --   --   --   --   1    --   --   --   --   --   --
  015               1                               --   --   --   1    --   --   --   --   5    --   2    --   --   --
  017               --                              --   --   --   --   4    --   --   --   --   --   --   --   --   --
  018               1                               --   6    --   --   --   1    --   --   --   --   --   --   --   --
  022               --                              --   1    --   --   --   --   --   --   --   --   --   --   --   --
  023               --                              --   --   --   --   --   1    --   --   --   --   --   --   --   --
  024               --                              --   --   --   --   --   --   --   --   --   --   --   1    --   --
  025               --                              --   --   1    --   --   --   --   --   --   --   --   --   --   --
  039               --                              --   --   --   --   --   --   1    --   --   --   --   --   --   --
  042               --                              --   --   --   --   --   --   --   1    --   --   --   --   --   --
  046               --                              --   --   --   --   --   --   --   --   --   --   1    --   --   --
  048               --                              --   --   --   --   --   8    --   --   --   --   --   --   --   --
  050               --                              --   --   --   --   --   1    --   --   --   --   --   --   --   --
  052               --                              --   --   --   --   --   1    --   --   --   --   --   --   --   --
  NC^2^             2                               --   --   --   1    --   --   1    --   --   --   --   --   --   --

1

The number of isolates that code for the respective TcdA variants within each ribotype subset are enumerated.

2

Isolates that do not code for full length TcdA proteins.

###### 

*C. difficile* isolates grouped by ribotype can code for multiple and sequence diverse TcdB variants.

  TcdB Variant^1^   Ribotype (number of isolates)                                                                    
  ----------------- ------------------------------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
  001               1                               --   1    --   2    --   --   2    --   --   --   --   --   --   --
  002               --                              --   --   --   --   --   92   --   --   --   --   --   --   --   --
  004               --                              --   --   --   --   --   --   --   --   --   11   18   --   10   --
  006               --                              --   --   --   --   --   --   --   --   --   --   1    --   --   --
  007               --                              --   --   --   3    --   --   --   --   --   --   --   --   --   --
  008               --                              --   --   1    3    --   3    5    2    --   --   --   --   --   --
  009               --                              --   --   --   --   7    --   --   --   --   --   --   15   --   --
  010               --                              --   4    --   --   --   1    --   --   --   --   --   --   --   --
  012               35                              21   --   1    36   2    --   --   5    5    --   2    --   --   --
  013               --                              --   --   1    --   --   --   --   --   --   --   --   --   --   --
  014               --                              --   --   --   1    --   --   --   --   --   --   --   --   --   --
  015               --                              --   --   --   --   --   --   --   12   --   --   --   --   --   1
  016               --                              --   --   --   --   4    --   --   --   --   --   --   --   --   --
  021               1                               --   --   3    --   --   --   --   --   --   --   --   --   --   --
  023               --                              --   --   --   --   --   --   --   --   --   --   --   1    --   --
  024               --                              --   --   --   --   --   --   --   --   --   --   --   1    --   --
  026               --                              --   --   --   --   --   --   --   1    --   --   --   --   --   1
  028               --                              --   --   --   1    --   --   --   --   --   --   --   --   --   --
  036               1                               --   --   --   --   --   --   --   --   --   --   --   --   --   --
  037               --                              --   --   --   --   --   --   --   1    --   --   --   --   --   --
  042               --                              --   --   --   --   --   --   --   --   --   --   --   1    --   --
  NC^2^             2                               --   2    --   1    --   --   1    --   --   --   --   --   --   --

1

The number of isolates that code for the respective TcdB variants within each ribotype subset are enumerated.

2

Isolates that do not code for full length TcdB proteins.

Using ST assignments, all but two of the isolates from this study could be grouped into one of five clades. With the exception of clade 4, the number and distribution of TcdA variants within each of the clades is more diverse than TcdB variants ([Supplementary Figure 1](#FS1){ref-type="supplementary-material"}).

Discussion {#S4}
==========

*C. difficile* infection is a worldwide public health issue and is now the most common healthcare-associated bacterial pathogen. It was estimated that during 2011 there were nearly half a million cases of CDI in the United States, associated with approximately 29,000 deaths ([@B28]). Several vaccine strategies for the prevention of CDI have been, or are currently, being evaluated in clinical trials and most of these have focused on the large single subunit glucosylating toxins, TcdA and TcdB as antigens ([@B4]). Clinical proof of concept for the selection of these toxins as *C. difficile* vaccine antigens has come from studies that were used to support the approval of Bezlotoxumab (ZINPLAVA^TM^, Merck) to reduce the recurrence of CDI in adult patients ([@B1]). Bezlotoxumab is a human monoclonal antibody that binds to a discontinuous epitope located within the CROP domain of TcdB ([@B35]). Since the CROP domain accounts for approximately 20% of the entire protein, a prophylactic vaccine approach able to generate a functional polyclonal response to additional and multiple epitopes across the entire toxin has the potential to prevent primary disease. Three prophylactic vaccines composed of full-length toxin open reading frames, or portions thereof, have been evaluated in clinical studies. A recombinant fusion protein that includes a portion of the TcdA and TcdB CROP domain from a single strain of *C. difficile* ([@B4]) has completed phase 2 testing (NCT02316470). The antigens included in the other investigational vaccines correspond to inactivated full length toxin proteins (i.e., toxoids TxdA, and TxdB) ([@B11]). Following a planned interim analysis in a phase 3 clinical study for one of the toxoid based vaccines (NCT01887912), the study was discontinued based on the low probability of meeting its primary objective ([@B40]). A bivalent toxoid-based vaccine composed of genetically and chemically inactivated toxoid antigens is in phase 3 clinical development (NCT03918629). Active immunization with these genetically and chemically modified full length versions of TcdA and TcdB has elicited a robust polyclonal antibody response in subjects 65--85 years of age ([@B43]).

Several molecular methods including WGS have been utilized to characterize *C. difficile* toxin genes for epidemiological analysis of CDI ([@B19]; [@B24]; [@B22]). Two of these, toxinotype ([@B39]) and the deduced amino acid sequence of the Receptor Binding Domain (RBD) of TcdB variants ([@B10]), have focused on toxin genotype of *C. difficile* isolates. However, neither method provides detailed insight into the sequence diversity of the complete open reading frame of the two large toxin proteins. An understanding of the toxin variants expressed by CDI isolates is critically important for an assessment of the breadth of the functional antibody response elicited following immunization with a bivalent toxoid vaccine. Demonstration that the polyclonal immune sera can neutralize the cytotoxicity of sequence diverse toxins is required for an evaluation of vaccine efficacy. Prediction of the breadth of the functional immune response to a toxin-based vaccine antigen needs to be framed in the context of toxin variant type determined from WGS, because isolate classification by ribotype is not representative of the diversity of toxin protein sequences.

The availability of *C. difficile* WGS data with deep sequence coverage, across the PaLoc in particular, is limited. In a recent study, analysis of WGS data from 906 *C. difficile* strains focused on questions related to bacterial adaptation for healthcare-mediated transmission, but did not investigate the diversity of the *tcdA* and *tcdB* alleles ([@B26]). The WGS of 478 *C. difficile* isolates have been determined in our study. Acceptance criteria for toxin variant assignment required greater than 35X coverage across both *tcdA* and *tcdB* with less than 10% sequence heterogeneity at any nucleotide position for at least one representative isolate. A total of 44 unique TcdA variants and 37 unique TcdB variants were identified, many of which had not previously been reported. The toxin variants with pairwise amino acid sequence identity furthest removed from TcdA001 and TcdB001 were TcdA013 (98% sequence identity) and TcdB032 (86.1% sequence identity), respectively. The ability of the immune response elicited by a toxoid antigen to neutralize the cytotoxicity of sequence diverse toxins remains to be experimentally tested. It should be noted that the origin of the *C. difficile* isolates evaluated in this study was largely restricted to North America and Europe. The TcdA and TcdB sequences of isolates from different geographic regions may uncover further toxin diversity. In addition, as the isolates collected in this study are not prevalence based the most frequent TcdA and TcdB variant types identified here may not be representative of prevalence among circulating CDI isolates.

Although both TcdA and TcdB play a role in CDI, several observations suggest that TcdB is the major virulence factor. In both murine and hamster models of *C. difficile* infection, TcdB was responsible for most of the intestinal damage whereas TcdA caused more superficial and localized damage ([@B6]). It is also worth noting that TcdA+/TcdB− *C. difficile* strains are extremely rare ([@B34]), whereas TcdA−/TcdB+ strains are not uncommon and have been associated with multiple disease outbreaks ([@B12]; [@B37]). The greater amino acid sequence diversity noted among the 37 TcdB variants compared with the 44 TcdA variants identified in this study could in part be the consequence of host immune pressure applied to the more virulent TcdB toxins.

Several isolates with deduced amino acid sequences shorter than TcdA001 have been identified in this collection. The majority of these are the product of in-frame stop codons in the glucosyl transferase or auto protease domains and therefore are not likely to code for a functional toxin. TcdA variants with either a deletion or a termination codon within the CROP domain have also been identified. Cell-culture based cytotoxicity assays are required to demonstrate whether these TcdA variants are functional. Previous work by Rupnik and Janezic has indicated that toxinotype VI and VII strains, with deletions in the CROP domain, do produce functional TcdA ([@B39]). It has also been reported that a TcdA mutant lacking the entire CROP domain is cytotoxic, able to enter human cells and cause cytotoxicity, albeit with reduced uptake ([@B15]). Among the isolates evaluated in this study, similar genetic changes in the sequences corresponding to the CROP domain of TcdB variants have not been identified. The larger number and length of repeat units in the TcdA CROP domain may render this locus more prone to genetic rearrangements than TcdB. Differences between the genes coding for the two toxins extend beyond the CROP domain. Examples of toxigenic isolates lacking any sequence coding for TcdA (TcdA−/TcdB+) are included in this collection and have been described in the literature ([@B47]). As noted earlier and despite their close proximity in the PaLoc, examples of TcdA+/TcdB− isolates, lacking *tcdB* sequences are not common ([@B34]). Our current understanding of the molecular detail of epithelial cell binding and uptake also differentiates the toxins from one another ([@B7]). Taken together, these observations suggest that evolution of the two toxins has been and will continue to be subject to different selection pressures. Relative to the highly conserved TcdA variants, the greater sequence diversity among TcdB variants described in this manuscript is consistent with this idea.

The same acceptance criteria for deep sequence coverage were applied in the analysis of WGS data corresponding to the genes coding for both subunits of the *C. difficile* binary toxin. The majority of isolates (*n* = 292, 61%) in this study did not code for binary toxin (e.g., genotyped as *cdtA*−*/cdtB*−). Consistent with literature reports indicating that CDI isolates typed as TcdA−/TcdB−/CDT+ are rare ([@B16]; [@B13]), there were no TcdA−/TcdB−/CDT+ isolates identified in this study. A study in a hamster model of CDI suggested that vaccination with bivalent TxdA and TxdB antigens did not fully protect from challenge with a TcdA+/TcdB+/CDT+ NAP1 strain and that the addition of binary toxin antigens to the vaccine greatly enhanced protection ([@B42]). Interestingly, human epidemic isolates 027/BI/NAP1 and 078/BK/NAP7 are both positive for binary toxin ([@B13]), whereas the emerging RT106 as well as RT017 isolates common in Asia are negative for binary toxin ([@B29]; [@B20]). The contribution of binary toxin to clinical CDI remains controversial.

*C. difficile* isolates can be grouped into five different clades based on ST assignments ([@B18]). Dingle et al. showed that 17 alleles coding for 13 deduced peptide sequences corresponding to the TcdB RBD segregate in parallel with clade assignment ([@B10]). That is, no single RBD allele was found in more than one clade. However, this study focused on just a small section of TcdB and did not capture the full sequence diversity of TcdB variants. In addition, the diversity of TcdA has not been taken into consideration. Using ST assignments from WGS data collected in our study, 476 of the 478 isolates can be placed into one of the 5 clades. Greater than half of the isolates (*n* = 276) are grouped into Clade 1 and these are genotypically diverse, including 49 different STs, 39 ribotypes, 24 TcdA variants and 22 TcdB variants. However, much like the clade-restricted observation for the RBD alleles, none of the 24 TcdA and 22 TcdB variants are coded for by strains other than those grouped to clade 1. The same conclusion can be drawn for strains associated with each clade. For example, while clade 5 strains are fewer in number (*n* = 45) and much less diverse (42 of these are ST11 and each code for TcdB004), all TcdA013 and TcdB004 variants are coded for by strains that are grouped to clade 5.

The Simpson's Diversity Index (SDI) analysis indicated that the distribution of TcdA variants within the respective clades is generally more diverse than the variants of TcdB ([Supplementary Figure 1](#FS1){ref-type="supplementary-material"}). Although both TcdA and TcdB are co-localized to the PaLoc, the variation in SDI suggested that TcdA and TcdB might have evolved in response to different evolutionary pressures. One interpretation is that point mutations in TcdA are sporadic and equally represented across phylogenetic clades (excluding clade 4 in this collection of strains). The variability noted among TcdB protein sequences can be postulated as the sum of sporadic point mutations together with pressure exerted from additional mechanisms. It is interesting to note that while three distinct cell surface receptors for TcdB have been identified, \[PVRL3 (or NECTIN3), CSPG4 and members of the Frizzled protein family\] ([@B27]; [@B49]; [@B45]), similar molecular binding detail has not been uncovered for TcdA. In fact, none of these receptors bind TcdA. In contrast to the CROP domain of TcdA, high-affinity glycan mediated binding for TcdB CROP at the cell surface has not been experimentally demonstrated ([@B14]). The molecular difference in host cell entry mechanisms utilized by TcdA and TcdB may contribute to the variation of SDI noted here.

To our knowledge, this is the first comprehensive WGS characterization of a large *C. difficile* isolate collection with a focused analysis of the sequence diversity among TcdA and TcdB toxins. From WGS data, we identified 44 TcdA variants and 37 TcdB variants, many of which were not previously documented. The relative lack of deep WGS data deposited in public databases could be due to technical challenges associated with the sequencing of *C. difficile* isolates using conventional methods, and in particular sequence determination across repetitive regions of the pathogenicity locus. We observed that neither ribotype nor ST assignment is predictive of the toxin genotype of *C. difficile* isolates. Specifically, isolates that are grouped together based on ribotype assignment can code for multiple sequence diverse TcdA and TcdB variants. We propose an amended nomenclature that describes both the ribotype and the TcdA and TcdB variant type for the purpose of *C. difficile* strain surveillance during vaccine efficacy trials. As the immune response to toxoid antigens will be polyclonal and not restricted to the RBD, it is essential that sequence diversity of the entire toxin proteins be considered in efforts to estimate vaccine efficacy. While challenges are associated with obtaining deep sequence coverage across the pathogenicity locus, WGS should be applied for *C. difficile* isolate typing together with ribotype determination to better guide *C. difficile* epidemiological studies and to help evaluate immunological approaches for the prevention of *C. difficile* disease.
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